Neuren Pharmaceuticals Ltd (NEU) - Total Assets

Latest as of June 2025: AU$331.25 Million AUD ≈ $234.38 Million USD

Based on the latest financial reports, Neuren Pharmaceuticals Ltd (NEU) holds total assets worth AU$331.25 Million AUD (≈ $234.38 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore NEU debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

Neuren Pharmaceuticals Ltd - Total Assets Trend (2000–2024)

This chart illustrates how Neuren Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. See Neuren Pharmaceuticals Ltd (NEU) shareholders funds for net asset value and shareholders' equity analysis.

Neuren Pharmaceuticals Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Neuren Pharmaceuticals Ltd's total assets of AU$331.25 Million consist of 97.5% current assets and 2.5% non-current assets.

Asset Category	Amount (AUD)	% of Total Assets
Cash & Equivalents	AU$0.00	0.8%
Accounts Receivable	AU$172.91 Million	42.2%
Inventory	AU$0.00	0.0%
Property, Plant & Equipment	AU$31.00K	0.0%
Intangible Assets	AU$0.00	0.0%
Goodwill	AU$0.00	0.0%

Asset Composition Trend (2000–2024)

This chart illustrates how Neuren Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NEU company net worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Neuren Pharmaceuticals Ltd's current assets represent 97.5% of total assets in 2024, an increase from 0.0% in 2000.
Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 89.6% in 2000.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
Asset Diversification: The largest asset category is accounts receivable at 42.2% of total assets.

Neuren Pharmaceuticals Ltd Competitors by Total Assets

Key competitors of Neuren Pharmaceuticals Ltd based on total assets are shown below.

Company	Country	Total Assets
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	China	CN¥8.59 Billion
Tubize-Fin BR:TUB	Belgium	€1.93 Billion
Sk Biopharmaceuticals Co Ltd KO:326030	Korea	₩1.20 Trillion
Tango Therapeutics Inc NASDAQ:TNGX	USA	$398.69 Million
TELIX Pharmaceuticals Ltd AU:TLX	Australia	AU$1.19 Billion
Xiamen Amoytop Biotech Co Ltd SHG:688278	China	CN¥3.21 Billion
Hangzhou Biotest Biotech Co Ltd SHG:688767	China	CN¥2.49 Billion
Theravance Biopharma Inc F:0TB	Germany	€415.46 Million

Neuren Pharmaceuticals Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	40.42	25.42	16.11
Quick Ratio	40.42	25.42	16.11
Cash Ratio	0.75	0.29	15.26
Working Capital	AU$312.32 Million	AU$219.07 Million	AU$9.08 Million

Neuren Pharmaceuticals Ltd - Advanced Valuation Insights

This section examines the relationship between Neuren Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	5.29
Latest Market Cap to Assets Ratio	4.07
Asset Growth Rate (YoY)	65.2%
Total Assets	AU$409.71 Million
Market Capitalization	$1.67 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values Neuren Pharmaceuticals Ltd's assets at a significant premium (4.07x), suggesting investors see substantial growth potential or unique competitive advantages.

Rapid Asset Growth: Neuren Pharmaceuticals Ltd's assets grew by 65.2% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Neuren Pharmaceuticals Ltd (2000–2024)

The table below shows the annual total assets of Neuren Pharmaceuticals Ltd from 2000 to 2024.

Year	Total Assets	Change
2024-12-31	AU$409.71 Million ≈ $289.89 Million	+65.22%
2023-12-31	AU$247.97 Million ≈ $175.45 Million	+473.12%
2022-12-31	AU$43.27 Million ≈ $30.61 Million	+8.02%
2021-12-31	AU$40.06 Million ≈ $28.34 Million	+60.53%
2020-12-31	AU$24.95 Million ≈ $17.66 Million	+73.21%
2019-12-31	AU$14.41 Million ≈ $10.19 Million	-45.93%
2018-12-31	AU$26.64 Million ≈ $18.85 Million	+48.47%
2017-12-31	AU$17.94 Million ≈ $12.70 Million	+188.95%
2016-12-31	AU$6.21 Million ≈ $4.39 Million	-63.26%
2015-12-31	AU$16.90 Million ≈ $11.96 Million	-23.53%
2014-12-31	AU$22.11 Million ≈ $15.64 Million	-16.31%
2013-12-31	AU$26.41 Million ≈ $18.69 Million	+211.41%
2012-12-31	AU$8.48 Million ≈ $6.00 Million	-23.84%
2011-12-31	AU$11.14 Million ≈ $7.88 Million	+94.79%
2010-12-31	AU$5.72 Million ≈ $4.05 Million	-44.41%
2009-12-31	AU$10.28 Million ≈ $7.28 Million	+20.37%
2008-12-31	AU$8.54 Million ≈ $6.05 Million	-41.42%
2007-12-31	AU$14.59 Million ≈ $10.32 Million	-25.29%
2006-12-31	AU$19.52 Million ≈ $13.81 Million	-44.54%
2005-12-31	AU$35.20 Million ≈ $24.91 Million	+171.60%
2004-12-31	AU$12.96 Million ≈ $9.17 Million	+1762.35%
2003-12-31	AU$696.00K ≈ $492.46K	-79.11%
2002-12-31	AU$3.33 Million ≈ $2.36 Million	-35.29%
2001-12-31	AU$5.15 Million ≈ $3.64 Million	+12.33%
2000-12-31	AU$4.58 Million ≈ $3.24 Million	--

About Neuren Pharmaceuticals Ltd

AU:NEU Australia Biotechnology

Market Cap

$1.67 Billion

AU$2.36 Billion AUD

Market Cap Rank

#6767 Global

#159 in Australia

Share Price

AU$18.61

Change (1 day)

+0.11%

52-Week Range

AU$11.28 - AU$21.98

All Time High

AU$25.11